Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023
- Revenue increased by 4% in Q4 2023 compared to Q4 2022.
- The company shipped 79 NovaSeq X instruments in Q4 2023 and 352 instruments for the fiscal year.
- Expect Core Illumina revenue to be approximately flat for fiscal year 2024.
- Revenue for fiscal year 2023 was down 2% from fiscal year 2022.
- GAAP diluted loss per share was $(1.11) for Q4 2023.
Insights
The reported revenue increase in Q4 2023 juxtaposed with the year-over-year decline in fiscal year revenue suggests a complex financial landscape for Illumina. The modest Q4 growth could indicate resilience in the company's product offerings, particularly the NovaSeq X instruments, despite broader market constraints. However, the annual revenue dip, albeit flat on a constant currency basis, raises concerns about the company's growth trajectory and potential headwinds in the life sciences sector.
Moreover, the GAAP diluted loss per share widening in Q4 2023 compared to the previous year, coupled with significant goodwill and intangible impairments related to the GRAIL segment, signals potential overvaluation issues in past acquisitions. This is mitigated somewhat by the non-GAAP diluted earnings, which remained stable year-over-year for Q4 and decreased for the fiscal year, implying operational challenges that are somewhat less dire when excluding certain non-recurring costs.
The divestiture of GRAIL is a strategic move likely aimed at streamlining operations and focusing on core competencies. This could be a positive step for Illumina, as it may alleviate some of the financial burden and refocus efforts on more profitable segments. However, the divestiture process's success and its impact on the company's financial health will be critical to monitor.
From a market perspective, Illumina's performance and forecast for flat Core Illumina revenue in fiscal year 2024 suggest a cautious outlook on the company's market position. Given the competitive nature of the genomic sequencing industry, it's imperative to evaluate how Illumina's product pipeline and innovation strategy align with evolving customer needs and market trends. The operating margin projection of approximately 20% indicates a focus on profitability, but it also sets expectations for operational efficiency improvements.
The divestment of GRAIL and the associated goodwill and intangible impairments reflect a reevaluation of strategic investments and could be indicative of broader industry challenges in monetizing advanced genomic technologies. The non-GAAP operating margin for Core Illumina, which excludes these impairments, may provide a clearer picture of the operational health of the company's primary business.
While the financials provide a quantitative measure of Illumina's performance, the legal and regulatory environment also plays a significant role. The divestiture of GRAIL following the European Commission's order suggests a complex legal landscape that Illumina must navigate. The outcome of the European Court of Justice appeal and the potential NHS rollout of Galleri in the UK are external factors that could influence the company's strategic decisions and financial results.
The mention of legal contingency and settlement costs in the financial statements highlights the ongoing legal considerations that can have material financial implications. Companies in the biotechnology and genomic sectors often face significant regulatory scrutiny and Illumina's ability to manage these legal challenges while executing its business strategy will be essential to its success.
- Revenue of
$1.12 billion 4% from Q4 2022 (up4% on a constant currency basis) - Revenue of
$4.50 billion 2% from fiscal year 2022 (flat on a constant currency basis) - Shipped 79 NovaSeq X instruments in Q4 2023 and 352 instruments for fiscal year 2023
- GAAP diluted loss per share of
$(1.11) $(0.89) - Non-GAAP diluted earnings per share of
$0.14 - GAAP diluted loss per share of
$(7.34) $821 million $(28.00) $3.91 billion - Non-GAAP diluted earnings per share of
$0.86 $2.12 - For fiscal year 2024, expect Core Illumina revenue that is approximately flat compared to 2023 and a Core Illumina non-GAAP operating margin of approximately
20% - On December 17, 2023, Illumina announced it will divest GRAIL. The GRAIL divestiture will be executed through a third-party sale or capital markets transaction, consistent with the European Commission's divestiture order, with the goal of finalizing the divestiture terms by the end of the second quarter of this year. The timing of Illumina's progress with the divestment is not affected by external factors, including, but not limited to, the outcome of the European Court of Justice appeal and the potential preliminary NHS rollout of Galleri in the
UK
"I'm pleased that in the fourth quarter, my first full quarter with the company, Illumina delivered results ahead of our expectations, driven by NovaSeq X instrument and consumables sales," said Jacob Thaysen, Chief Executive Officer. "While our customers generally remain constrained in their purchasing, we are well-positioned for growth as market conditions improve. Illumina is focused on three key priorities to accelerate value creation: driving our top line; focusing on operational excellence, including boosting productivity, cost savings, and customer-focused innovation; and working to resolve GRAIL as quickly as possible."
Fourth quarter consolidated results
GAAP | Non-GAAP (a) | ||||||
Dollars in millions, except per share amounts | Q4 2023 | Q4 2022 | Q4 2023 | Q4 2022 | |||
Revenue | $ 1,122 | $ 1,083 | $ 1,122 | $ 1,083 | |||
Gross margin | 60.1 % | 62.1 % | 64.4 % | 66.6 % | |||
Research and development ("R&D") expense | $ 341 | $ 346 | $ 329 | $ 339 | |||
Selling, general and administrative ("SG&A") expense | $ 485 | $ 432 | $ 342 | $ 351 | |||
Goodwill and intangible impairment | $ 6 | $ — | $ — | $ — | |||
Legal contingency and settlement | $ 6 | $ 21 | $ — | $ — | |||
Operating (loss) profit | $ (164) | $ (127) | $ 51 | $ 31 | |||
Operating margin | (14.6) % | (11.7) % | 4.6 % | 2.9 % | |||
Tax provision (benefit) | $ 8 | $ (28) | $ 26 | $ 9 | |||
Tax rate | (4.9) % | 16.8 % | 55.4 % | 29.3 % | |||
Net (loss) income | $ (176) | $ (140) | $ 22 | $ 22 | |||
Diluted (loss) earnings per share | $ (1.11) | $ (0.89) | $ 0.14 | $ 0.14 | |||
(a) See the tables included in the "Results of Operations - Non-GAAP" section below for reconciliations of these GAAP and non-GAAP financial measures. |
Capital expenditures for free cash flow purposes were
Fourth quarter segment results
Illumina has two reportable segments, Core Illumina and GRAIL.
Core Illumina
GAAP | Non-GAAP (a) | ||||||
Dollars in millions | Q4 2023 | Q4 2022 | Q4 2023 | Q4 2022 | |||
Revenue (b) | $ 1,097 | $ 1,065 | $ 1,097 | $ 1,065 | |||
Gross margin (c) | 63.3 % | 65.9 % | 64.7 % | 67.3 % | |||
R&D expense | $ 260 | $ 264 | $ 248 | $ 257 | |||
SG&A expense | $ 391 | $ 347 | $ 259 | $ 271 | |||
Goodwill and intangible impairment | $ 6 | $ — | $ — | $ — | |||
Legal contingency and settlement | $ 6 | $ 21 | $ — | $ — | |||
Operating profit | $ 33 | $ 70 | $ 203 | $ 190 | |||
Operating margin | 3.0 % | 6.6 % | 18.5 % | 17.8 % | |||
(a) See Table 3 included in the "Results of Operations - Non-GAAP" section below for reconciliations of these GAAP and non-GAAP financial measures. |
(b) Core Illumina revenue for Q4 2023 was up |
(c) The year-over-year decrease in gross margin was primarily driven by the mix of lower margin strategic partnership revenue, lower instrument margins due to the NovaSeq X launch, which is typical with a new platform introduction, and increased field services and installation costs, partially offset by lower freight costs. |
GRAIL
GAAP | Non-GAAP (a) | ||||||
In millions | Q4 2023 | Q4 2022 | Q4 2023 | Q4 2022 | |||
Revenue | $ 30 | $ 23 | $ 30 | $ 23 | |||
Gross (loss) profit | $ (19) | $ (26) | $ 14 | $ 8 | |||
R&D expense | $ 84 | $ 85 | $ 84 | $ 85 | |||
SG&A expense | $ 94 | $ 86 | $ 83 | $ 81 | |||
Operating loss | $ (197) | $ (197) | $ (152) | $ (159) | |||
(a) See Table 3 included in the "Results of Operations - Non-GAAP" section below for reconciliations of these GAAP and non-GAAP financial measures. |
Fiscal year 2023 consolidated results
GAAP | Non-GAAP (a) | ||||||
Dollars in millions, except per share amounts | 2023 | 2022 | 2023 | 2022 | |||
Revenue | $ 4,504 | $ 4,584 | $ 4,504 | $ 4,584 | |||
Gross margin | 60.9 % | 64.8 % | 65.3 % | 68.6 % | |||
R&D expense | $ 1,354 | $ 1,321 | $ 1,325 | $ 1,313 | |||
SG&A expense | $ 1,612 | $ 1,297 | $ 1,367 | $ 1,346 | |||
Goodwill and intangible impairment (b) | $ 827 | $ 3,914 | $ — | $ — | |||
Legal contingency and settlement | $ 20 | $ 619 | $ — | $ — | |||
Operating (loss) profit | $ (1,069) | $ (4,179) | $ 247 | $ 487 | |||
Operating margin | (23.7) % | (91.2) % | 5.5 % | 10.6 % | |||
Tax provision | $ 44 | $ 68 | $ 98 | $ 118 | |||
Tax rate | (3.9) % | (1.6) % | 41.8 % | 26.0 % | |||
Net (loss) income | $ (1,161) | $ (4,404) | $ 137 | $ 336 | |||
Diluted (loss) earnings per share | $ (7.34) | $ (28.00) | $ 0.86 | $ 2.12 | |||
(a) See the tables included in "Results of Operations - Non-GAAP" section below for reconciliations of these GAAP and non-GAAP financial measures. |
(b) The company recognized |
Capital expenditures for free cash flow purposes were
Fiscal year 2023 segment results
Core Illumina
GAAP | Non-GAAP (a) | ||||||
In millions | 2023 | 2022 | 2023 | 2022 | |||
Revenue (b) | $ 4,438 | $ 4,553 | $ 4,438 | $ 4,553 | |||
Gross margin | 64.4 % | 68.2 % | 65.8 % | 69.1 % | |||
R&D expense | $ 1,030 | $ 1,004 | $ 1,001 | $ 996 | |||
SG&A expense | $ 1,248 | $ 1,003 | $ 1,032 | $ 1,069 | |||
Goodwill and intangible impairment | $ 6 | $ — | $ — | $ — | |||
Legal contingency and settlement | $ 20 | $ 619 | $ — | $ — | |||
Operating profit | $ 552 | $ 481 | $ 885 | $ 1,081 | |||
Operating margin | 12.4 % | 10.6 % | 19.9 % | 23.8 % | |||
(a) See Table 3 included in the "Results of Operations - Non-GAAP" section below for reconciliations of these GAAP and non-GAAP financial measures. |
(b) Core Illumina revenue for 2023 was down |
GRAIL
GAAP | Non-GAAP (a) | ||||||
In millions | 2023 | 2022 | 2023 | 2022 | |||
Revenue | $ 93 | $ 55 | $ 93 | $ 55 | |||
Gross (loss) profit | $ (96) | $ (117) | $ 38 | $ 17 | |||
R&D expense | $ 338 | $ 330 | $ 338 | $ 330 | |||
SG&A expense | $ 366 | $ 296 | $ 337 | $ 279 | |||
Goodwill and intangible impairment | $ 821 | $ 3,914 | $ — | $ — | |||
Operating loss | $ (1,621) | $ (4,657) | $ (638) | $ (592) | |||
(a) See Table 3 included in the "Results of Operations - Non-GAAP" section below for reconciliations of these GAAP and non-GAAP financial measures. |
Key announcements by Illumina since Illumina's last earnings release
- Announced the decision to divest GRAIL, executed through a third-party sale or capital markets transaction, with the goal of finalizing terms by the end of the second quarter 2024
- Submitted a confidential, draft registration statement on Form 10 related to the GRAIL divestment to the
U.S. Securities and Exchange Commission - Signed agreement with Janssen Research & Development, LLC (Janssen) to collaborate on the development of Illumina's novel molecular residual disease (MRD) assay
- Expanded the Alliance for Genomic Discovery, adding Bristol Myers Squibb (BMS), GSK and Novo Nordisk to join founding member organizations AbbVie, Amgen, AstraZeneca, Bayer, and Merck, who together will co-fund the whole-genome sequencing (WGS) of 250,000 data samples and have access to the resulting data for use in drug discovery and therapeutic development
- Launched the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs)
- Conducted a stewardship-focused non-deal roadshow led by Illumina's independent board directors; held discussions with shareholders owning more than half of outstanding shares
A full list of recent Illumina announcements can be found in the company's News Center.
Key announcements by GRAIL since Illumina's last earnings release
- Highlighted the presentation of analytical and clinical validation data on a novel prognostic test in early-stage lung cancer, generated through collaboration with the Samsung Medical Centre and AstraZeneca, demonstrating sensitive and specific detection of circulating tumor DNA (ctDNA) for Lung Adenocarcinoma (LUAD) at a clinically meaningful threshold for disease prognostication
- Announced that it will initiate Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study) following the
U.S. Food and Drug Administration's (FDA) approval of GRAIL's Investigational Device Exemption (IDE) application and the Centers for Medicare and Medicaid Services' (CMS) approval for Medicare coverage of the study - Announced BeniComp, a customized health plan provider, and Curative Insurance, a pioneering healthcare services company, will make Galleri available to eligible patients
A full list of recent GRAIL announcements can be found in GRAIL's Newsroom.
Financial outlook and guidance
For fiscal year 2024, the company expects Core Illumina revenue to be approximately flat compared to fiscal year 2023 and Core Illumina non-GAAP operating margin to be approximately
The company provides forward-looking guidance on a non-GAAP basis. The company is unable to provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures because it is unable to predict with reasonable certainty the financial impact of items such as acquisition-related expenses, gains and losses from our strategic investments, fair value adjustments related to contingent consideration and contingent value rights, potential future asset impairments, restructuring activities, and the ultimate outcome of pending litigation without unreasonable effort. These items are uncertain, inherently difficult to predict, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, the company is unable to address the significance of the unavailable information, which could be material to future results.
Conference call information
The conference call will begin at 2 p.m. Pacific Time (5 p.m. Eastern Time) on Thursday, February 8, 2024. Interested parties may access the live teleconference through the Investor Info section of Illumina's website at investor.illumina.com. Alternatively, individuals can access the call by dialing 877.400.0505 or +1.323.701.0225 outside
A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days following.
Statement regarding use of non-GAAP financial measures
The company reports non-GAAP results for diluted earnings per share, net income, gross margin, operating expenses, including research and development expense, selling general and administrative expense, and from time to time, as applicable, legal contingencies and settlement, and goodwill and intangible impairment, operating income (loss), operating margin, gross profit (loss), other income (expense), tax provision, constant currency revenue growth, and free cash flow (on a consolidated and, as applicable, segment basis for our Core Illumina and GRAIL segments) in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The company's financial measures under GAAP include substantial charges such as amortization of acquired intangible assets among others that are listed in the itemized reconciliations between GAAP and non-GAAP financial measures included in this press release, as well as the effects of currency translation. Management has excluded the effects of these items in non-GAAP measures to assist investors in analyzing and assessing past and future operating performance, including in the non-GAAP measures related to our Core Illumina and GRAIL segments. Additionally, non-GAAP net income and diluted earnings per share are key components of the financial metrics utilized by the company's board of directors to measure, in part, management's performance and determine significant elements of management's compensation.
The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.
Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) changes in the rate of growth in the markets we serve; (ii) the volume, timing and mix of customer orders among our products and services; (iii) our ability to adjust our operating expenses to align with our revenue expectations; (iv) our ability to manufacture robust instrumentation and consumables; (v) the success of products and services competitive with our own; (vi) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; (vii) the impact of recently launched or pre-announced products and services on existing products and services; (viii) our ability to modify our business strategies to accomplish our desired operational goals; (ix) our ability to realize the anticipated benefits from prior or future actions to streamline and improve our R&D processes, reduce our operating expenses and maximize our revenue growth; (x) our ability to further develop and commercialize our instruments, consumables, and products; (xi) to deploy new products, services, and applications, and to expand the markets for our technology platforms; (xii) the risks and costs associated with our ongoing inability to integrate GRAIL due to the transitional measures imposed on us by the European Commission as a result of their prohibition of our acquisition of GRAIL and orders issued by the European Commission and the Federal Trade Commission requiring that we divest GRAIL; (xiii) the risks and costs associated with the expected divestment of GRAIL, including the possibility that the terms on which we divest all or a portion of the assets or equity interests of GRAIL are materially worse than those on which we acquired GRAIL; (xiv) our ability to satisfy the necessary conditions to consummate the divestiture of GRAIL on a timely basis or at all, due to the requirements set by the European Commission; (xv) the risk that disruptions from the consummation of our acquisition of GRAIL and associated legal or regulatory proceedings, including appeals, or obligations will harm our business, including current plans and operations; (xvi) the risk of incurring additional fines associated with the consummation of our acquisition of GRAIL; (xvii) our ability to obtain approval by third-party payors to reimburse patients for our products; (xviii) our ability to obtain regulatory clearance for our products from government agencies; (xix) our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business; (xx) uncertainty, or adverse economic and business conditions, including as a result of slowing or uncertain economic growth or armed conflict; (xxi) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments and (xxii) legislative, regulatory and economic developments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in
Illumina, Inc. Condensed Consolidated Balance Sheets (In millions) | |||
December 31, | January 1, | ||
ASSETS | (unaudited) | ||
Current assets: | |||
Cash and cash equivalents | $ 1,048 | $ 2,011 | |
Short-term investments | 6 | 26 | |
Accounts receivable, net | 734 | 671 | |
Inventory, net | 587 | 568 | |
Prepaid expenses and other current assets | 234 | 285 | |
Total current assets | 2,609 | 3,561 | |
Property and equipment, net | 1,007 | 1,091 | |
Operating lease right-of-use assets | 544 | 653 | |
Goodwill | 2,545 | 3,239 | |
Intangible assets, net | 2,993 | 3,285 | |
Other assets | 413 | 423 | |
Total assets | $ 10,111 | $ 12,252 | |
LIABILITIES AND STOCKHOLDERS' EQUITY | |||
Current liabilities: | |||
Accounts payable | $ 245 | $ 293 | |
Accrued liabilities | 1,325 | 1,232 | |
Term notes, current portion | — | 500 | |
Convertible senior notes, current portion | — | 748 | |
Total current liabilities | 1,570 | 2,773 | |
Operating lease liabilities | 687 | 744 | |
Term notes | 1,489 | 1,487 | |
Other long-term liabilities | 620 | 649 | |
Stockholders' equity | 5,745 | 6,599 | |
Total liabilities and stockholders' equity | $ 10,111 | $ 12,252 | |
Illumina, Inc. Condensed Consolidated Statements of Operations (In millions, except per share amounts) (unaudited) | |||||||
Three Months Ended | Year Ended | ||||||
December 31, | January 1, | December 31, | January 1, | ||||
Revenue: | |||||||
Product revenue | $ 923 | $ 913 | $ 3,787 | $ 3,953 | |||
Service and other revenue | 199 | 170 | 717 | 631 | |||
Total revenue | 1,122 | 1,083 | 4,504 | 4,584 | |||
Cost of revenue: | |||||||
Cost of product revenue (a) | 293 | 279 | 1,177 | 1,144 | |||
Cost of service and other revenue (a) | 108 | 84 | 392 | 295 | |||
Amortization of acquired intangible assets | 47 | 48 | 191 | 173 | |||
Total cost of revenue | 448 | 411 | 1,760 | 1,612 | |||
Gross profit | 674 | 672 | 2,744 | 2,972 | |||
Operating expense: | |||||||
Research and development (a) | 341 | 346 | 1,354 | 1,321 | |||
Selling, general and administrative (a) | 485 | 432 | 1,612 | 1,297 | |||
Goodwill and intangible impairment | 6 | — | 827 | 3,914 | |||
Legal contingency and settlement | 6 | 21 | 20 | 619 | |||
Total operating expense | 838 | 799 | 3,813 | 7,151 | |||
Loss from operations | (164) | (127) | (1,069) | (4,179) | |||
Other expense, net | (4) | (41) | (48) | (157) | |||
Loss before income taxes | (168) | (168) | (1,117) | (4,336) | |||
Provision (benefit) for income taxes | 8 | (28) | 44 | 68 | |||
Net loss | $ (176) | $ (140) | $ (1,161) | $ (4,404) | |||
Loss per share: | |||||||
Basic | $ (1.11) | $ (0.89) | $ (7.34) | $ (28.00) | |||
Diluted | $ (1.11) | $ (0.89) | $ (7.34) | $ (28.00) | |||
Shares used in computing loss per share: | |||||||
Basic | 159 | 158 | 158 | 157 | |||
Diluted | 159 | 158 | 158 | 157 | |||
(a) Includes stock-based compensation expense for stock-based awards: | |||||||
Three Months Ended | Year Ended | ||||||
December 31, | January 1, | December 31, | January 1, | ||||
Cost of product revenue | $ 7 | $ 6 | $ 29 | $ 26 | |||
Cost of service and other revenue | 2 | 1 | 7 | 6 | |||
Research and development | 39 | 40 | 155 | 153 | |||
Selling, general and administrative | 48 | 51 | 189 | 181 | |||
Stock-based compensation expense before taxes | $ 96 | $ 98 | $ 380 | $ 366 | |||
Illumina, Inc. (In millions) (unaudited) | |||||||
Three Months Ended | Year Ended | ||||||
December 31, | January 1, | December 31, | January 1, | ||||
Net cash provided by operating activities | $ 224 | $ 147 | $ 478 | $ 392 | |||
Net cash used in investing activities | (84) | (102) | (231) | (591) | |||
Net cash (used in) provided by financing activities | (27) | 956 | (1,210) | 1,000 | |||
Effect of exchange rate changes on cash and cash equivalents | 8 | 10 | — | (22) | |||
Net increase (decrease) in cash and cash equivalents | 121 | 1,011 | (963) | 779 | |||
Cash and cash equivalents, beginning of period | 927 | 1,000 | 2,011 | 1,232 | |||
Cash and cash equivalents, end of period | $ 1,048 | $ 2,011 | $ 1,048 | $ 2,011 | |||
Calculation of free cash flow: | |||||||
Net cash provided by operating activities | $ 224 | $ 147 | $ 478 | $ 392 | |||
Purchases of property and equipment | (51) | (88) | (195) | (286) | |||
Free cash flow (a) | $ 173 | $ 59 | $ 283 | $ 106 | |||
(a) Free cash flow, which is a non-GAAP financial measure, is calculated as net cash provided by operating activities reduced by purchases of property and equipment. Free cash flow is useful to management as it is one of the metrics used to evaluate our performance and to compare us with other companies in our industry. However, our calculation of free cash flow may not be comparable to similar measures used by other companies. |
Illumina, Inc. Results of Operations - Revenue by Segment (Dollars in millions) (unaudited) | |||||||||||
Three Months Ended | Year Ended | ||||||||||
December 31, | January 1, | % Change | December 31, | January 1, | % Change | ||||||
Consolidated revenue | $ 1,122 | $ 1,083 | 4 % | $ 4,504 | $ 4,584 | (2) % | |||||
Less: Hedge gains | 10 | 21 | 18 | 53 | |||||||
Consolidated revenue, excluding hedge effect | 1,112 | 1,062 | 4,486 | 4,531 | |||||||
Less: Exchange rate effect | 10 | — | (25) | — | |||||||
Consolidated constant currency revenue (a) | $ 1,102 | $ 1,062 | 4 % | $ 4,511 | $ 4,531 | — | |||||
Core Illumina revenue | $ 1,097 | $ 1,065 | 3 % | $ 4,438 | $ 4,553 | (3) % | |||||
Less: Hedge gains | 10 | 21 | 18 | 53 | |||||||
Core Illumina revenue, excluding hedge effect | 1,087 | 1,044 | 4,420 | 4,500 | |||||||
Less: Exchange rate effect | 10 | — | (25) | — | |||||||
Core Illumina constant currency revenue (a) | $ 1,077 | $ 1,044 | 3 % | $ 4,445 | $ 4,500 | (1) % | |||||
(a) Constant currency revenue growth, which is a non-GAAP financial measure, is calculated using comparative prior period foreign exchange rates to translate current period revenue, net of the effects of hedges. |
Illumina, Inc. Results of Operations - Non-GAAP (In millions, except per share amounts) (unaudited)
| |||||||
TABLE 1: CONSOLIDATED RECONCILIATION BETWEEN GAAP AND NON-GAAP DILUTED (LOSS) EARNINGS PER SHARE: | |||||||
Three Months Ended | Year Ended | ||||||
December 31, | January 1, | December 31, | January 1, | ||||
GAAP loss per share - diluted | $ (1.11) | $ (0.89) | $ (7.34) | $ (28.00) | |||
Cost of revenue (b) | 0.30 | 0.31 | 1.24 | 1.10 | |||
R&D expense (b) | 0.08 | 0.04 | 0.18 | 0.05 | |||
SG&A expense (b) | 0.90 | 0.51 | 1.54 | (0.31) | |||
Goodwill and intangible impairment (b) | 0.04 | — | 5.23 | 24.93 | |||
Legal contingency and settlement (b) | 0.03 | 0.14 | 0.13 | 3.94 | |||
Other expense, net (b) | 0.01 | 0.26 | 0.23 | 0.78 | |||
GILTI and | (0.01) | (0.01) | 0.38 | 0.38 | |||
Incremental non-GAAP tax expense (d) | (0.28) | (0.31) | (0.96) | (0.83) | |||
Income tax provision (e) | 0.18 | 0.09 | 0.23 | 0.11 | |||
Effect of dilutive shares (f) | — | — | — | (0.03) | |||
Non-GAAP earnings per share - diluted (a) | $ 0.14 | $ 0.14 | $ 0.86 | $ 2.12 | |||
GAAP diluted shares | 159 | 158 | 158 | 157 | |||
Non-GAAP dilutive shares (f) | — | — | — | 2 | |||
Non-GAAP diluted shares | 159 | 158 | 158 | 159 | |||
TABLE 2: CONSOLIDATED RECONCILIATION BETWEEN GAAP AND NON-GAAP NET (LOSS) INCOME: | |||||||
Three Months Ended | Year Ended | ||||||
December 31, | January 1, | December 31, | January 1, | ||||
GAAP net loss | $ (176) | $ (140) | $ (1,161) | $ (4,404) | |||
Cost of revenue (b) | 48 | 49 | 196 | 173 | |||
R&D expense (b) | 12 | 7 | 29 | 8 | |||
SG&A expense (b) | 143 | 81 | 244 | (48) | |||
Goodwill and intangible impairment (b) | 6 | — | 827 | 3,914 | |||
Legal contingency and settlement (b) | 6 | 21 | 20 | 619 | |||
Other expense, net (b) | 1 | 41 | 36 | 124 | |||
GILTI and | (2) | (1) | 61 | 60 | |||
Incremental non-GAAP tax expense (d) | (44) | (51) | (152) | (129) | |||
Income tax provision (e) | 28 | 15 | 37 | 19 | |||
Non-GAAP net income (a) | 22 | 22 | 137 | 336 | |||
Add: interest expense on convertible notes, net of tax (g) | — | — | — | 2 | |||
Non-GAAP net income for diluted earnings per share | $ 22 | $ 22 | $ 137 | $ 338 | |||
All amounts in tables are rounded to the nearest millions, except as otherwise noted. As a result, certain amounts may not recalculate using the rounded amounts provided. |
(a) Non-GAAP net income and diluted earnings per share exclude the effects of the pro forma adjustments as detailed above. Non-GAAP net income and diluted earnings per share are key components of the financial metrics utilized by the company's board of directors to measure, in part, management's performance and determine significant elements of management's compensation. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing our past and future operating performance. |
(b) Refer to the Itemized Reconciliations between GAAP and Non-GAAP Results of Operations for the components of these amounts. |
(c) Amounts represent the impact of GRAIL pre-acquisition net operating losses on GILTI and the utilization of |
(d) Incremental non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed. |
(e) Amounts represent the difference between book and tax accounting related to stock-based compensation cost. |
(f) In loss periods, GAAP basic loss per share and diluted loss per share are identical since the effect of potentially dilutive shares is anti-dilutive and therefore excluded. For non-GAAP diluted earnings per share, the impact of potentially dilutive shares from our convertible senior notes and equity awards is included and is calculated based on the sum of weighted-average common shares and potentially dilutive shares outstanding during 2022. |
(g) Amount represents interest expense on the 2023 Convertible Senior Notes, net of any income tax effects, which is added back to the numerator used to calculate non-GAAP diluted earnings per share, for purposes of the if-converted method, as it would have a dilutive effect on the calculation of non-GAAP diluted earnings per share. |
Illumina, Inc. Results of Operations - Non-GAAP (continued) (Dollars in millions) (unaudited)
| |||||||||
TABLE 3: ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP RESULTS OF OPERATIONS AS A PERCENT OF REVENUE: | |||||||||
Three Months Ended | |||||||||
December 31, 2023 | |||||||||
Core Illumina | GRAIL | Eliminations | Consolidated | ||||||
GAAP gross profit (loss) (b) | $ 695 | 63.3 % | $ (19) | $ (2) | $ 674 | 60.1 % | |||
Amortization of acquired intangible assets | 14 | 1.3 % | 33 | — | 47 | 4.2 % | |||
Restructuring (g) | 1 | 0.1 % | — | — | 1 | 0.1 % | |||
Non-GAAP gross profit (a) | $ 710 | 64.7 % | $ 14 | $ (2) | $ 722 | 64.4 % | |||
GAAP R&D expense | $ 260 | 23.7 % | $ 84 | $ (3) | $ 341 | 30.4 % | |||
Acquisition-related expenses (d) | (1) | (0.1) % | — | — | (1) | (0.1) % | |||
Restructuring (g) | (11) | (1.0) % | — | — | (11) | (1.0) % | |||
Non-GAAP R&D expense | $ 248 | 22.6 % | $ 84 | $ (3) | $ 329 | 29.3 % | |||
GAAP SG&A expense | $ 391 | 35.6 % | $ 94 | $ — | $ 485 | 43.2 % | |||
Amortization of acquired intangible assets | — | — | (1) | — | (1) | (0.1) % | |||
Contingent consideration liabilities (c) | (58) | (5.2) % | — | — | (58) | (5.1) % | |||
Acquisition-related expenses (d) | (24) | (2.2) % | (9) | — | (33) | (2.9) % | |||
Restructuring (g) | (48) | (4.4) % | (1) | — | (49) | (4.4) % | |||
Proxy contest | (2) | (0.2) % | — | — | (2) | (0.2) % | |||
Non-GAAP SG&A expense | $ 259 | 23.6 % | $ 83 | $ — | $ 342 | 30.5 % | |||
GAAP goodwill and intangible impairment | $ 6 | 0.5 % | $ — | $ — | $ 6 | 0.5 % | |||
Intangible (IPR&D) impairment (i) | (6) | (0.5) % | — | — | (6) | (0.5) % | |||
Non-GAAP goodwill and intangible impairment | $ — | — | $ — | $ — | $ — | — | |||
GAAP legal contingency and settlement | $ 6 | 0.5 % | $ — | $ — | $ 6 | 0.5 % | |||
Legal contingency and settlement (h) | (6) | (0.5) % | — | — | (6) | (0.5) % | |||
Non-GAAP legal contingency and settlement | $ — | — | $ — | $ — | $ — | — | |||
GAAP operating profit (loss) | $ 33 | 3.0 % | $ (197) | $ — | $ (164) | (14.6) % | |||
Cost of revenue | 15 | 1.4 % | 33 | — | 48 | 4.3 % | |||
R&D costs | 12 | 1.1 % | — | — | 12 | 1.1 % | |||
SG&A costs | 131 | 12.0 % | 12 | — | 143 | 12.8 % | |||
Goodwill and intangible impairment | 6 | 0.5 % | — | — | 6 | 0.5 % | |||
Legal contingency and settlement | 6 | 0.5 % | — | — | 6 | 0.5 % | |||
Non-GAAP operating profit (loss) (a) | $ 203 | 18.5 % | $ (152) | $ — | $ 51 | 4.6 % | |||
GAAP other (expense) income, net | $ (6) | (0.5) % | $ 2 | $ — | $ (4) | (0.4) % | |||
Gain on Helix contingent value right (f) | (2) | (0.2) % | — | — | (2) | (0.2) % | |||
Unrealized foreign currency loss on EC fine (j) | 3 | 0.3 % | — | — | 3 | 0.3 % | |||
Non-GAAP other (expense) income, net (a) | $ (5) | (0.4) % | $ 2 | $ — | $ (3) | (0.3) % | |||
Illumina, Inc. Results of Operations - Non-GAAP (continued) (Dollars in millions) (unaudited)
| |||||||||
TABLE 3 (CONTINUED): ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP RESULTS OF OPERATIONS AS A PERCENT OF REVENUE: | |||||||||
Three Months Ended | |||||||||
January 1, 2023 | |||||||||
Core Illumina | GRAIL | Eliminations | Consolidated | ||||||
GAAP gross profit (loss) (b) | $ 702 | 65.9 % | $ (26) | $ (4) | $ 672 | 62.1 % | |||
Amortization of acquired intangible assets | 14 | 1.3 % | 34 | — | 48 | 4.4 % | |||
Restructuring (g) | 1 | 0.1 % | — | — | 1 | 0.1 % | |||
Non-GAAP gross profit (a) | $ 717 | 67.3 % | $ 8 | $ (4) | $ 721 | 66.6 % | |||
GAAP R&D expense | $ 264 | 24.7 % | $ 85 | $ (3) | $ 346 | 31.9 % | |||
Acquisition-related expenses (d) | (1) | (0.1) % | — | — | (1) | (0.1) % | |||
Restructuring (g) | (6) | (0.5) % | — | — | (6) | (0.5) % | |||
Non-GAAP R&D expense | $ 257 | 24.1 % | $ 85 | $ (3) | $ 339 | 31.3 % | |||
GAAP SG&A expense | $ 347 | 32.6 % | $ 86 | $ (1) | $ 432 | 39.9 % | |||
Amortization of acquired intangible assets | — | — | (1) | — | (1) | (0.1) % | |||
Contingent consideration liabilities (c) | (25) | (2.4) % | — | — | (25) | (2.3) % | |||
Acquisition-related expenses (d) | (27) | (2.5) % | (4) | — | (31) | (2.9) % | |||
Restructuring (g) | (24) | (2.3) % | — | — | (24) | (2.2) % | |||
Non-GAAP SG&A expense | $ 271 | 25.4 % | $ 81 | $ (1) | $ 351 | 32.4 % | |||
GAAP legal contingency and settlement | $ 21 | 2.0 % | $ — | $ — | $ 21 | 1.9 % | |||
Legal contingency and settlement (h) | (21) | (2.0) % | — | — | (21) | (1.9) % | |||
Non-GAAP legal contingency and settlement | $ — | — | $ — | $ — | $ — | — | |||
GAAP operating profit (loss) | $ 70 | 6.6 % | $ (197) | $ — | $ (127) | (11.7) % | |||
Cost of revenue | 15 | 1.4 % | 34 | — | 49 | 4.5 % | |||
R&D costs | 7 | 0.6 % | — | — | 7 | 0.6 % | |||
SG&A costs | 77 | 7.2 % | 4 | — | 81 | 7.6 % | |||
Legal contingency and settlement | 21 | 2.0 % | — | — | 21 | 1.9 % | |||
Non-GAAP operating profit (loss) (a) | $ 190 | 17.8 % | $ (159) | $ — | $ 31 | 2.9 % | |||
GAAP other (expense) income, net | $ (42) | (3.9) % | $ 1 | $ — | $ (41) | (3.8) % | |||
Strategic investment related loss, net (e) | 42 | 3.9 % | — | — | 42 | 3.9 % | |||
Gain on Helix contingent value right (f) | (1) | (0.1) % | — | — | (1) | (0.1) % | |||
Non-GAAP other (expense) income, net (a) | $ (1) | (0.1) % | $ 1 | $ — | $ — | — | |||
Illumina, Inc. Results of Operations - Non-GAAP (continued) (Dollars in millions) (unaudited)
| |||||||||
TABLE 3 (CONTINUED): ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP RESULTS OF OPERATIONS AS A PERCENT OF REVENUE: | |||||||||
Year Ended | |||||||||
December 31, 2023 | |||||||||
Core Illumina | GRAIL | Eliminations | Consolidated | ||||||
GAAP gross profit (loss) (b) | 64.4 % | $ (96) | $ (16) | $ 2,744 | 60.9 % | ||||
Amortization of acquired intangible assets | 57 | 1.3 % | 134 | — | 191 | 4.3 % | |||
Restructuring (g) | 5 | 0.1 % | — | — | 5 | 0.1 % | |||
Non-GAAP gross profit (a) | 65.8 % | $ 38 | $ (16) | $ 2,940 | 65.3 % | ||||
GAAP R&D expense | 23.2 % | $ 338 | $ (14) | $ 1,354 | 30.1 % | ||||
Acquisition-related expenses (d) | (2) | — | — | — | (2) | — | |||
Restructuring (g) | (27) | (0.6) % | — | — | (27) | (0.7) % | |||
Non-GAAP R&D expense | 22.6 % | $ 338 | $ (14) | $ 1,325 | 29.4 % | ||||
GAAP SG&A expense | 28.1 % | $ 366 | $ (2) | $ 1,612 | 35.8 % | ||||
Amortization of acquired intangible assets | (1) | — | (4) | — | (5) | (0.1) % | |||
Contingent consideration liabilities (c) | 24 | 0.5 % | — | — | 24 | 0.5 % | |||
Acquisition-related expenses (d) | (88) | (1.9) % | (21) | — | (109) | (2.4) % | |||
Restructuring (g) | (119) | (2.7) % | (4) | — | (123) | (2.7) % | |||
Proxy contest | (32) | (0.7) % | — | — | (32) | (0.7) % | |||
Non-GAAP SG&A expense | 23.3 % | $ 337 | $ (2) | $ 1,367 | 30.4 % | ||||
GAAP goodwill and intangible impairment | $ 6 | 0.1 % | $ 821 | $ — | $ 827 | 18.3 % | |||
Goodwill impairment (i) | — | — | (712) | — | (712) | (15.7) % | |||
Intangible (IPR&D) impairment (i) | (6) | (0.1) % | (109) | — | (115) | (2.6) % | |||
Non-GAAP goodwill and intangible impairment | $ — | — | $ — | $ — | $ — | — | |||
GAAP legal contingency and settlement | $ 20 | 0.4 % | $ — | $ — | $ 20 | 0.4 % | |||
Legal contingency and settlement (h) | (20) | (0.4) % | — | — | (20) | (0.4) % | |||
Non-GAAP legal contingency and settlement | $ — | — | $ — | $ — | $ — | — | |||
GAAP operating profit (loss) | $ 552 | 12.4 % | $ — | (23.7) % | |||||
Cost of revenue | 62 | 1.5 % | 134 | — | 196 | 4.4 % | |||
R&D costs | 29 | 0.6 % | — | — | 29 | 0.7 % | |||
SG&A costs | 216 | 4.9 % | 28 | — | 244 | 5.4 % | |||
Goodwill and intangible impairment | 6 | 0.1 % | 821 | — | 827 | 18.3 % | |||
Legal contingency and settlement | 20 | 0.4 % | — | — | 20 | 0.4 % | |||
Non-GAAP operating profit (loss) (a) | $ 885 | 19.9 % | $ (638) | $ — | $ 247 | 5.5 % | |||
GAAP other (expense) income, net | $ (58) | (1.3) % | $ 10 | $ — | $ (48) | (1.1) % | |||
Strategic investment related loss, net (e) | 35 | 0.8 % | — | — | 35 | 0.8 % | |||
Gain on Helix contingent value right (f) | (10) | (0.2) % | — | — | (10) | (0.2) % | |||
Unrealized foreign currency loss on EC fine (j) | 11 | 0.2 % | — | — | 11 | 0.2 % | |||
Non-GAAP other (expense) income, net (a) | $ (22) | (0.5) % | $ 10 | $ — | $ (12) | (0.3) % | |||
Illumina, Inc. Results of Operations - Non-GAAP (continued) (Dollars in millions) (unaudited)
| |||||||||
TABLE 3 (CONTINUED): ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP RESULTS OF OPERATIONS AS A PERCENT OF REVENUE: | |||||||||
Year Ended | |||||||||
January 1, 2023 | |||||||||
Core Illumina | GRAIL | Eliminations | Consolidated | ||||||
GAAP gross profit (loss) (b) | 68.2 % | $ (117) | $ (18) | $ 2,972 | 64.8 % | ||||
Amortization of acquired intangible assets | 38 | 0.9 % | 134 | — | 172 | 3.8 % | |||
Restructuring (g) | 1 | — | — | — | 1 | — | |||
Non-GAAP gross profit (a) | 69.1 % | $ 17 | $ (18) | $ 3,145 | 68.6 % | ||||
GAAP R&D expense | 22.0 % | $ 330 | $ (13) | $ 1,321 | 28.8 % | ||||
Acquisition-related expenses (d) | (2) | — | — | — | (2) | — | |||
Restructuring (g) | (6) | (0.1) % | — | — | (6) | (0.2) % | |||
Non-GAAP R&D expense | $ 996 | 21.9 % | $ 330 | $ (13) | $ 1,313 | 28.6 % | |||
GAAP SG&A expense | 22.0 % | $ 296 | $ (2) | $ 1,297 | 28.3 % | ||||
Amortization of acquired intangible assets | (1) | — | (4) | — | (5) | (0.1) % | |||
Contingent consideration liabilities (c) | 205 | 4.5 % | — | — | 205 | 4.5 % | |||
Acquisition-related expenses (d) | (114) | (2.5) % | (13) | — | (127) | (2.8) % | |||
Restructuring (g) | (24) | (0.5) % | — | — | (24) | (0.5) % | |||
Non-GAAP SG&A expense | 23.5 % | $ 279 | $ (2) | $ 1,346 | 29.4 % | ||||
GAAP legal contingency and settlement | $ 619 | 13.6 % | $ — | $ — | $ 619 | 13.5 % | |||
Legal contingency and settlement (h) | (619) | (13.6) % | — | — | (619) | (13.5) % | |||
Non-GAAP legal contingency and settlement | $ — | — | $ — | $ — | $ — | — | |||
GAAP goodwill and intangible impairment | $ — | — | $ 3,914 | $ — | $ 3,914 | 85.4 % | |||
Goodwill impairment (i) | — | — | (3,914) | — | (3,914) | (85.4) % | |||
Non-GAAP goodwill and intangible impairment | $ — | — | $ — | $ — | $ — | — | |||
GAAP operating profit (loss) | $ 481 | 10.6 % | $ (3) | (91.2) % | |||||
Cost of revenue | 39 | 0.9 % | 134 | — | 173 | 3.8 % | |||
R&D costs | 8 | 0.1 % | — | — | 8 | 0.2 % | |||
SG&A costs | (66) | (1.4) % | 17 | — | (48) | (1.1) % | |||
Legal contingency and settlement | 619 | 13.6 % | — | — | 619 | 13.5 % | |||
Goodwill impairment | — | — | 3,914 | — | 3,914 | 85.4 % | |||
Non-GAAP operating profit (loss) (a) | 23.8 % | $ (592) | $ (3) | $ 487 | 10.6 % | ||||
GAAP other (expense) income, net | $ (159) | (3.5) % | $ 2 | $ — | $ (157) | (3.4) % | |||
Strategic investment related loss, net (e) | 117 | 2.6 % | — | — | 117 | 2.5 % | |||
Loss on Helix contingent value right (f) | 7 | 0.1 % | — | — | 7 | 0.2 % | |||
Non-GAAP other (expense) income, net (a) | $ (35) | (0.8) % | $ 2 | $ — | $ (33) | (0.7) % | |||
All amounts in tables are rounded to the nearest millions, except as otherwise noted. As a result, certain amounts may not recalculate using the rounded amounts provided. Percentages of revenue are calculated based on the revenue of the respective segment. |
(a) Non-GAAP gross profit, included within non-GAAP operating profit (loss), is a key measure of the effectiveness and efficiency of manufacturing processes, product mix and the average selling prices of our products and services. Non-GAAP operating profit (loss) and non-GAAP other (expense) income, net exclude the effects of the pro forma adjustments as detailed above. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing past and future operating performance, including in the non-GAAP measures related to our Core Illumina and GRAIL segments. |
(b) Reconciling amounts are recorded in cost of revenue. |
(c) Amounts consist primarily of fair value adjustments for our contingent consideration liability related to GRAIL. |
(d) Amounts consist primarily of legal expenses related to the acquisition of GRAIL. |
(e) Amounts consist primarily of mark-to-market adjustments and impairments from our strategic investments. |
(f) Amounts consist of fair value adjustments related to our Helix contingent value right. |
(g) Amounts consist primarily of lease and other asset impairments and employee severance costs related to restructuring activities. |
(h) Amount for Q4 2023 consists primarily of accrued interest on the fine imposed by the European Commission. Amount for FY 2023 also consists of a loss related to a patent litigation settlement in Q1 2023, an adjustment recorded in Q2 2023 to our accrual for the fine imposed by the European Commission in July 2023, and a gain related to a patent litigation settlement in Q3 2023. Amount for Q4 2022 consists of a legal accrual related to our litigation with RavGen and an adjustment made to our previously recorded legal accrual for the fine that the European Commission imposed on us. Amount for FY 2022 also consists of expense of |
(i) Amount for Q4 2023 consists of an IPR&D intangible asset impairment related to our Core Illumina segment. Amount for FY 2023 also consists of goodwill and IPR&D intangible asset impairments related to our GRAIL segment. Amount for FY 2022 consists of goodwill impairment related to our GRAIL segment. |
(j) Amounts consist of unrealized gains/losses related to foreign currency balance sheet remeasurement of the EC fine liability and unrealized mark-to-market gains/losses on the hedge associated with the EC fine. |
Illumina, Inc. Results of Operations - Non-GAAP (continued) (Dollars in millions) (unaudited)
| |||||
TABLE 4: CONSOLIDATED ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP TAX PROVISION (BENEFIT): | |||||
Three Months Ended | Year Ended | ||||
December 31, | December 31, | ||||
GAAP tax provision | $ 8 | (4.9) % | $ 44 | (3.9) % | |
Incremental non-GAAP tax expense (b) | 44 | 152 | |||
Income tax provision (c) | (28) | (37) | |||
GILTI and | 2 | (61) | |||
Non-GAAP tax provision (a) | $ 26 | 55.4 % | $ 98 | 41.8 % | |
Three Months Ended | Year Ended | ||||
January 1, | January 1, | ||||
GAAP tax (benefit) provision | $ (28) | 16.8 % | $ 68 | (1.6) % | |
Incremental non-GAAP tax expense (b) | 51 | 129 | |||
Income tax provision (c) | (15) | (19) | |||
GILTI and | 1 | (60) | |||
Non-GAAP tax provision (a) | $ 9 | 29.3 % | $ 118 | 26.0 % | |
(a) Non-GAAP tax provision excludes the effects of the pro forma adjustments as detailed above. Management has excluded the effects of these items in this measure to assist investors in analyzing and assessing past and future operating performance. |
(b) Incremental non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed in Table 2. |
(c) Amounts represent the difference between book and tax accounting related to stock-based compensation cost. |
(d) Amounts represent the impact of GRAIL pre-acquisition net operating losses on GILTI and the utilization of |
Investors:
Salli Schwartz
+1.858.291.6421
ir@illumina.com
Media:
David McAlpine
+1.347.327.1336
pr@illumina.com
View original content:https://www.prnewswire.com/news-releases/illumina-reports-financial-results-for-fourth-quarter-and-fiscal-year-2023-302057998.html
SOURCE Illumina, Inc.
FAQ
What was Illumina's Q4 2023 revenue?
How many NovaSeq X instruments did Illumina ship in Q4 2023?
What is the ticker symbol for Illumina?
What is the expected Core Illumina revenue for fiscal year 2024?
